Company: CDLX
Filing Date: 2025-04-03
Form Type: ARS
Source: 0001666071-25-000048
Chunk: 104

Company: Cardlytics, Inc.
Filing Date: 2025-04-03
Form: ARS
Chunk 104
---
304) Balance – December 31, 2024 51,257 $ 10 $ 1,366,958 $ 3,601 $ (1,300,576) $ 69,993 Year Ended December 31, 2023: Additional Paid-In Capital Accumulated Other Comprehensive Income (loss) Accumulated Deficit Total Common Stock Shares Amount Balance – December 31, 2022 33,477 $ 9 $ 1,182,568 $ 5,598 $ (976,570) $ 211,605 Exercise of common stock options 10 — 54 — — 54 Stock-based compensation — — 43,466 — — 43,466 Issuance of restricted stock 2,930 — — — — — Issuance of common stock 2,755 — 15,171 — — 15,171 Issuance of common stock under the ESPP 556 — 2,335 — — 2,335 Other comprehensive loss — — — (3,131) — (3,131) Net loss — — — — (134,702) (134,702) Balance – December 31, 2023 39,728 $ 9 $ 1,243,594 $ 2,467 $ (1,111,272) $ 134,798 See notes to the consolidated financial statements 67

CARDLYTICS, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Amounts in thousands) Year Ended December 31, 2022: Additional Paid-In Capital Accumulated Other Comprehensive Income (loss) Accumulated Deficit Total Common Stock Shares Amount Balance – December 31, 2021 33,534 $ 9 $ 1,212,823 $ 486 $ (522,618) $ 690,700 Cumulative effect upon adoption of ASU — — (51,417) — 11,312 (40,105) Exercise of common stock options 23 — 418 — — 418 Stock-based compensation — — 46,810 — — 46,810 Issuance of restricted stock 986 — — — — — Common stock to be issued for the acquisition of Entertainment 173 — 11,937 — — 11,937 Issuance of common stock under the ESPP 167 — 1,997 — — 1,997 Repurchase and cancellation of common stock (1,406) — (40,000) —